UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 266

Sortiert nach

Adoptive immunotherapy with cells from tumor-draining lymph nodes activated and expanded in vitro

Methods in cell biology, 2024, Vol.183, p.355

2024

Volltextzugriff (PDF)

Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27

Journal of clinical oncology, 2012-11, Vol.30 (32), p.3960-3966

2012

Volltextzugriff (PDF)

Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies

Cancers, 2020-08, Vol.12 (9), p.2392

2020

Volltextzugriff (PDF)

Neighborhood disadvantage and biological aging biomarkers among breast cancer patients

Scientific reports, 2022-06, Vol.12 (1), p.11006-11006, Article 11006

2022

Volltextzugriff (PDF)

Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27

Journal of clinical oncology, 2008-02, Vol.26 (5), p.778-785

2008

Volltextzugriff (PDF)

Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden

Surgery, 2013-06, Vol.153 (6), p.771-778

2013

Volltextzugriff (PDF)

Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function

Journal of translational medicine, 2009-10, Vol.7 (1), p.89-89, Article 89

2009

Volltextzugriff (PDF)

Angiopoietin pathway gene expression associated with poor breast cancer survival

Breast cancer research and treatment, 2017-02, Vol.162 (1), p.191-198

2017

Volltextzugriff (PDF)

Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27

Journal of clinical oncology, 2006-05, Vol.24 (13), p.2019-2027

2006

Volltextzugriff (PDF)

Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer

The New England journal of medicine, 2012-01, Vol.366 (4), p.310-320

2012

Volltextzugriff (PDF)

GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells

Breast cancer research and treatment, 2010-08, Vol.123 (1), p.39-49

2010

Volltextzugriff (PDF)

Sentinel Node Biopsy After Neoadjuvant Systemic Therapy for Breast Cancer: The Method Matters

Annals of surgical oncology, 2019-08, Vol.26 (8), p.2316-2318

2019

Volltextzugriff (PDF)

Papillary lesions of the breast: To excise or observe?

The breast journal, 2018-05, Vol.24 (3), p.350-355

2018

Volltextzugriff (PDF)

Near-infrared imaging of adoptive immune cell therapy in breast cancer model using cell membrane labeling

PloS one, 2014-10, Vol.9 (10), p.e109162-e109162

2014

Volltextzugriff (PDF)

Perceived Stress Levels, Chemotherapy, Radiation Treatment and Tumor Characteristics Are Associated with a Persistent Increased Frequency of Somatic Chromosomal Instability in Women Diagnosed with Breast Cancer: A One Year Longitudinal Study

PloS one, 2015-07, Vol.10 (7), p.e0133380-e0133380

2015

Volltextzugriff (PDF)

The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27

Journal of clinical oncology, 2003-11, Vol.21 (22), p.4165-4174

2003

Volltextzugriff (PDF)

Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice

International immunopharmacology, 2009-07, Vol.9 (7), p.900-909

2009

Volltextzugriff (PDF)

Expansion of T Cells with Interleukin-21 for Adoptive Immunotherapy of Murine Mammary Carcinoma

International journal of molecular sciences, 2017-02, Vol.18 (2), p.270-270

2017

Volltextzugriff (PDF)

Using the 21‐gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial

Journal of surgical oncology, 2017-06, Vol.115 (8), p.917-923

2017

Volltextzugriff (PDF)

If we build it they will come: targeting the immune response to breast cancer

NPJ breast cancer, 2019-10, Vol.5 (1), p.1-13, Article 37

2019

Volltextzugriff (PDF)

Local and distant tumor dormancy during early stage breast cancer are associated with the predominance of infiltrating T effector subsets

Breast cancer research : BCR, 2020-10, Vol.22 (1), p.116-116, Article 116

2020

Volltextzugriff (PDF)

Autophagy-deficient breast cancer shows early tumor recurrence and escape from dormancy

Oncotarget, 2018-04, Vol.9 (31), p.22113-22122

2018

Volltextzugriff (PDF)

1 – 25 von 266

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(243)
Mit Volltextzugriff
(245)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(266)
Japanisch
(16)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Adoptive immunotherapy with cells from tumor-draining lymph nodes activated and expanded in vitro

Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27

Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies

Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial

Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial

Neighborhood disadvantage and biological aging biomarkers among breast cancer patients

Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27

Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden

Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function

Angiopoietin pathway gene expression associated with poor breast cancer survival

Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27

Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer

GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells

Sentinel Node Biopsy After Neoadjuvant Systemic Therapy for Breast Cancer: The Method Matters

Papillary lesions of the breast: To excise or observe?

Near-infrared imaging of adoptive immune cell therapy in breast cancer model using cell membrane labeling

Perceived Stress Levels, Chemotherapy, Radiation Treatment and Tumor Characteristics Are Associated with a Persistent Increased Frequency of Somatic Chromosomal Instability in Women Diagnosed with Breast Cancer: A One Year Longitudinal Study

The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27

Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice

Expansion of T Cells with Interleukin-21 for Adoptive Immunotherapy of Murine Mammary Carcinoma

Using the 21‐gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial

If we build it they will come: targeting the immune response to breast cancer

Local and distant tumor dormancy during early stage breast cancer are associated with the predominance of infiltrating T effector subsets

Autophagy-deficient breast cancer shows early tumor recurrence and escape from dormancy

Suchergebnisse filtern